Ratings by Mizuho (Joseph Catanzaro)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/24/2026 | Apogee Therapeutics Inc | APGE | Downgrade | Neutral (N/A) |
132.55 (132.92) |
0.28% | Details | |
| 6/8/2026 | Tango Therapeutics Inc. | TNGX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/22/2026 | Q32 Bio Inc. | QTTB | New Coverage | Outperform (N/A) |
5.67 (11.58) |
104.23% | Details | |
| 5/14/2026 | Tango Therapeutics Inc. | TNGX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2026 | Upstream Bio | UPB | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2026 | Avalo Therapeutics Inc. | AVTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/12/2026 | Erasca Inc | ERAS | Maintain | Outperform (N/A) |
|
Details | ||
| 4/27/2026 | Erasca Inc | ERAS | Maintain | Outperform (N/A) |
|
Details | ||
| 4/23/2026 | Revolution | RVMD | Maintain | Outperform (N/A) |
|
Details | ||
| 4/15/2026 | Climb Bio | CLYM | New Coverage | Outperform (N/A) |
8.63 (12.30) |
42.53% | Details | |
| 4/14/2026 | Revolution | RVMD | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/13/2026 | Spyre | SYRE | Maintain | Outperform (N/A) |
|
Details | ||
| 4/13/2026 | Spyre | SYRE | Maintain | Outperform (N/A) |
|
Details | ||
| 4/9/2026 | Revolution | RVMD | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/30/2026 | Eikon Therapeutics Inc. | EIKN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/30/2026 | Apogee Therapeutics Inc | APGE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/23/2026 | Apogee Therapeutics Inc | APGE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/13/2026 | Erasca Inc | ERAS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/11/2026 | Tango Therapeutics Inc. | TNGX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2026 | Eikon Therapeutics Inc. | EIKN | New Coverage | Outperform (N/A) |
13.64 (9.61) |
-29.55% | Details | |
| 2/26/2026 | Revolution | RVMD | Maintain | Outperform (N/A) |
|
Details | ||
| 2/23/2026 | Tango Therapeutics Inc. | TNGX | New Coverage | Outperform (N/A) |
12.35 (28.95) |
134.41% | Details | |
| 1/27/2026 | Erasca Inc | ERAS | New Coverage | Outperform (N/A) |
9.96 (15.01) |
50.7% | Details | |
| 1/13/2026 | Revolution | RVMD | Maintain | Outperform (N/A) |
|
Details | ||
| 12/19/2025 | Upstream Bio | UPB | New Coverage | Outperform (N/A) |
29.32 (6.56) |
-77.63% | Details | |
| 12/18/2025 | Bicara Therapeutics Inc | BCAX | New Coverage | Neutral (N/A) |
18.15 (25.81) |
42.2% | Details | |
| 12/18/2025 | Spyre | SYRE | New Coverage | Outperform (N/A) |
32.97 (85.91) |
160.57% | Details | |
| 12/18/2025 | Avalo Therapeutics Inc. | AVTX | New Coverage | Outperform (N/A) |
18.82 (18.20) |
-3.29% | Details | |
| 12/11/2025 | Kymera Therapeutics | KYMR | Maintain | Outperform (N/A) |
|
Details | ||
| 12/10/2025 | Nurix | NRIX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/21/2025 | Nurix | NRIX | New Coverage | Outperform (N/A) |
9.84 (19.68) |
100% | Details | |
| 10/21/2025 | Revolution | RVMD | New Coverage | Outperform (N/A) |
54.10 (168.45) |
211.37% | Details | |
| 10/21/2025 | Celldex Therapeutics | CLDX | New Coverage | Outperform (N/A) |
26.83 (33.42) |
24.56% | Details | |
| 10/21/2025 | Apogee Therapeutics Inc | APGE | New Coverage | Outperform (N/A) |
55.15 (132.55) |
140.34% | Details | |
| 10/21/2025 | Kymera Therapeutics | KYMR | New Coverage | Outperform (N/A) |
59.83 (100.25) |
67.56% | Details |
